⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23906460 | 0.78 | — | — | |
| SCHEMBL24265775 | 0.73 | GSK3B (0.38) | — | |
| SCHEMBL21670037 | 0.71 | — | — | |
| SCHEMBL3259059 | 0.71 | — | — | |
| SCHEMBL314712 | 0.71 | — | — | |
| SCHEMBL4505993 | 0.71 | — | — | |
| SCHEMBL28781338 | 0.71 | LMNA (0.38) | — | |
| SCHEMBL23917456 | 0.70 | GSK3B (0.36) | — | |
| SCHEMBL23917476 | 0.70 | GSK3B (0.36) | — | |
| SCHEMBL17754596 | 0.70 | PDPK1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717691-A1 | USE OF BMPR1B INHIBITOR IN INDUCED DEVELOPMENT, AND INDUCTION CULTURE MEDIUM | Iregene Therapeutics Co., Ltd (CN) | 2026-04-01 | — | — | EP | disclosed |
| US-12514859-B2 | Pyrazole pyrimidine derivative and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2026-01-06 | — | — | US | disclosed |
| US-20250049793-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-02-13 | — | — | US | disclosed |
| CN-119264055-A | WDR5 inhibitor and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024239187-A1 | USE OF BMPR1B INHIBITOR IN INDUCED DEVELOPMENT, AND INDUCTION CULTURE MEDIUM | 睿健医药科技(苏州)有限公司 | 2024-11-28 | — | — | WO | disclosed |
| CN-118995607-A | Application of BMPR1B inhibitor in induced development and induced culture medium | 睿健医药科技(苏州)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994114-A | Pyrazolyl piperazinone compounds, pharmaceutical compositions and application thereof | 睿健医药科技(苏州)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-11925641-B2 | Pyrazole pyrimidine derivative and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-03-12 | — | — | US | disclosed |
| CN-108137562-B | Pyrazolopyrimidine derivative and use thereof | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3331877-B1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2021-09-22 | — | — | EP | disclosed |
| EP-2091944-B1 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011050160-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
| EP-2091944-A2 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | Pfizer, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008059370-A2 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-05-22 | — | — | WO | disclosed |
| EP-1425015-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6825208-B2 | SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |